Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keenova Therapeutics plcNONE · Entity 28960 | Director | July 15, 2026 | July 18, 2026 |
| Mereo BioPharma Group plcMREO · Entity 7264 | Director | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keenova Therapeutics plc
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,718 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 4,406 · Balance 9,718 F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
Mereo BioPharma Group plc
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2036-02-26 | Direct | 66,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 66,000 · Balance 66,000 F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
| Deferred Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 96,163 |
Reported balance
After 2026-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-26 · Grant · Acquired 96,163 · Balance 96,163 F3: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F3: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:57 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 4,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-084780 · tm2620763-6_4seq1.xml · derivative · entry 1 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,718 Underlying: Ordinary Shares · 4,406 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070516 · tm2616870-1_4seq1.xml · derivative · entry 4 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,312 Underlying: Ordinary Shares · 3,579 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F4 · derivative.exercise_date: The RSUs, which were granted on August 14, 2025 and October 20, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F4 · derivative.expiration_date: The RSUs, which were granted on August 14, 2025 and October 20, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 2,930 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-070516 · tm2616870-1_4seq1.xml · derivative · entry 3 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,891 Underlying: Ordinary Shares · 2,930 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person entered into an agreement with the Issuer pursuant to which the Reporting Person forfeited the right to receive 2,930 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the Reporting Person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5 · price: The number of RSUs forfeited is based on a percentage. F4 · derivative.exercise_date: The RSUs, which were granted on August 14, 2025 and October 20, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F4 · derivative.expiration_date: The RSUs, which were granted on August 14, 2025 and October 20, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Tax withholdingOrdinary Shares | 825 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-070516 · tm2616870-1_4seq1.xml · nonDerivative · entry 2 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,541 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 3,579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-070516 · tm2616870-1_4seq1.xml · nonDerivative · entry 1 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantDeferred Restricted Stock Units · Derivative | 96,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082830 · ownership.xml · derivative · entry 2 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,163 Underlying: American Depository Shares · 96,163 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 66,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001193125-26-082830 · ownership.xml · derivative · entry 1 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: American Depositary Shares · 66,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 01:57 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 5,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-019927 · tm267115-7_4seq1.xml · derivative · entry 1 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,821 Underlying: Ordinary Shares · 5,312 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: Each RSU will fully vest on February 23, 2027. F2 · derivative.expiration_date: Each RSU will fully vest on February 23, 2027. F3 · balance_after: Reflects that the Reporting Person received 1,093 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health. Read SEC document |
| October 20, 2025 Filed Oct 21, 2025 00:01 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 1,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-100948 · tm2529059-1_4seq1.xml · derivative · entry 1 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,416 Underlying: Ordinary Shares · 1,354 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 01:06 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 4,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-079949 · tm2523680-8_4seq1.xml · derivative · entry 1 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,062 Underlying: Ordinary Shares · 4,062 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantDeferred Restricted Stock Units · Derivative | 13,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015426 · ownership.xml · derivative · entry 2 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,719 Underlying: American Depository Shares · 13,719 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer Read SEC document |
| February 05, 2025 Filed Feb 6, 2025 21:30 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 55,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0000950170-25-015426 · ownership.xml · derivative · entry 1 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: American Depositary Shares · 55,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:15 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantDeferred Restricted Stock Units · Derivative | 14,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-013269 · ownership.xml · derivative · entry 2 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,139 Underlying: American Depository Shares · 14,139 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:15 UTC | Mereo BioPharma Group plc MREO · Entity 7264 | GrantShare Options (Right to buy) · Derivative | 45,000 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0000950170-24-013269 · ownership.xml · derivative · entry 1 Yoskowitz Marc J · CIK 0001617306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: American Depository Shares · 45,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.